General MedicationsORALStandard
LUBIPROSTONE
LUBIPROSTONE
Standard Dose
8MCG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview LUBIPROSTONE is listed in Drugs@FDA under application 218640 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient LUBIPROSTONE Form and strength CAPSULE;ORAL - 8MCG Sponsor ASCENT PHARMS INC Submission history Latest submission status date: 2025-01-02 00:00:00.
Structured Monograph
Clinical summary
Approval overview LUBIPROSTONE is listed in Drugs@FDA under application 218640 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient LUBIPROSTONE Form and strength CAPSULE;ORAL - 8MCG Sponsor ASCENT PHARMS INC Submission history Latest submission status date: 2025-01-02 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.